HS

Hesarahalli Shivanna Latha

Active Director Director DIN 08241374
DIN 08241374 First appointment Sep 2018 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Hesarahalli Shivanna Latha

Data last updated:

Hesarahalli Shivanna Latha is a Director at Chiraksh Pharma Private Limited (since 2018). The company operates in Pharma.

DIN 08241374
Primary Designation Director
Industry Pharma
First Appointment 27 Sep 2018
Oldest Company Age 8 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Chiraksh Pharma Private Limited U24304KA2018PTC116972
Director27 Sep 20182018Active

Board colleagues of Hesarahalli Shivanna Latha

Directorship timeline

Open interactive timeline →
Chiraksh Pharma Private Limited
Premium access

Shareholding and investment profile for Hesarahalli Shivanna Latha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hesarahalli Shivanna Latha

Hesarahalli Shivanna Latha currently holds 1 directorship: Chiraksh Pharma Private Limited (Director, since 27 Sep 2018).

Hesarahalli Shivanna Latha was first appointed on 27 Sep 2018 as Director at Chiraksh Pharma Private Limited.

The current boards of Hesarahalli Shivanna Latha's companies include Pura Kallappa Shadakshari (Chiraksh Pharma Private Limited), Ramesh Parmar Kunal (Chiraksh Pharma Private Limited), Yugal Vinod Parmar (Chiraksh Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available